Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.65 USD | -2.37% |
|
+8.55% | +179.66% |
05-21 | DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis | CI |
05-21 | Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+179.66% | 51.21M | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- DRRX Stock
- News DURECT Corporation
- Durect Gets FDA Breakthrough Therapy Designation for Alcohol-Related Hepatitis Treatment